nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2D6—Fingolimod—multiple sclerosis	0.0627	0.187	CbGbCtD
Paroxetine—ABCB1—Methylprednisolone—multiple sclerosis	0.0429	0.128	CbGbCtD
Paroxetine—CYP2B6—Dexamethasone—multiple sclerosis	0.0316	0.0944	CbGbCtD
Paroxetine—ABCB1—Mitoxantrone—multiple sclerosis	0.0313	0.0934	CbGbCtD
Paroxetine—ABCB1—Betamethasone—multiple sclerosis	0.0279	0.0832	CbGbCtD
Paroxetine—ABCB1—Prednisolone—multiple sclerosis	0.0275	0.0821	CbGbCtD
Paroxetine—ABCB1—Prednisone—multiple sclerosis	0.026	0.0775	CbGbCtD
Paroxetine—CYP2C8—Dexamethasone—multiple sclerosis	0.024	0.0715	CbGbCtD
Paroxetine—TACR1—trigeminal nerve—multiple sclerosis	0.0226	0.158	CbGeAlD
Paroxetine—HTR2A—trigeminal nucleus—multiple sclerosis	0.0209	0.147	CbGeAlD
Paroxetine—CYP2C9—Dexamethasone—multiple sclerosis	0.0167	0.0499	CbGbCtD
Paroxetine—ABCB1—Dexamethasone—multiple sclerosis	0.0162	0.0484	CbGbCtD
Paroxetine—CYP2D6—Dexamethasone—multiple sclerosis	0.0153	0.0456	CbGbCtD
Paroxetine—ABCB1—Methotrexate—multiple sclerosis	0.013	0.0389	CbGbCtD
Paroxetine—TACR1—peripheral nervous system—multiple sclerosis	0.0106	0.074	CbGeAlD
Paroxetine—TACR1—nerve—multiple sclerosis	0.00824	0.0577	CbGeAlD
Paroxetine—HTR2A—trigeminal nerve—multiple sclerosis	0.0055	0.0386	CbGeAlD
Paroxetine—SLC6A3—nerve—multiple sclerosis	0.00414	0.029	CbGeAlD
Paroxetine—HTR2A—pons—multiple sclerosis	0.00387	0.0271	CbGeAlD
Paroxetine—TACR1—brainstem—multiple sclerosis	0.00354	0.0248	CbGeAlD
Paroxetine—SLC6A2—nerve—multiple sclerosis	0.00334	0.0234	CbGeAlD
Paroxetine—HTR2A—pineal body—multiple sclerosis	0.00276	0.0194	CbGeAlD
Paroxetine—HTR2A—peripheral nervous system—multiple sclerosis	0.00258	0.0181	CbGeAlD
Paroxetine—TACR1—spinal cord—multiple sclerosis	0.0022	0.0154	CbGeAlD
Paroxetine—HTR2A—nerve—multiple sclerosis	0.00201	0.0141	CbGeAlD
Paroxetine—TACR1—nervous system—multiple sclerosis	0.00185	0.013	CbGeAlD
Paroxetine—TACR1—central nervous system—multiple sclerosis	0.00178	0.0125	CbGeAlD
Paroxetine—SLC6A3—brainstem—multiple sclerosis	0.00178	0.0125	CbGeAlD
Paroxetine—CHRM4—nervous system—multiple sclerosis	0.00174	0.0122	CbGeAlD
Paroxetine—CHRM4—central nervous system—multiple sclerosis	0.00168	0.0118	CbGeAlD
Paroxetine—SLC6A4—brainstem—multiple sclerosis	0.00163	0.0114	CbGeAlD
Paroxetine—SLC6A2—brainstem—multiple sclerosis	0.00143	0.0101	CbGeAlD
Paroxetine—TACR1—brain—multiple sclerosis	0.00142	0.00992	CbGeAlD
Paroxetine—CHRM5—nervous system—multiple sclerosis	0.00136	0.00954	CbGeAlD
Paroxetine—CHRM4—brain—multiple sclerosis	0.00133	0.00933	CbGeAlD
Paroxetine—CHRM5—central nervous system—multiple sclerosis	0.00131	0.00919	CbGeAlD
Paroxetine—SLC6A3—midbrain—multiple sclerosis	0.00113	0.00794	CbGeAlD
Paroxetine—SLC6A3—spinal cord—multiple sclerosis	0.00111	0.00775	CbGeAlD
Paroxetine—CHRM5—brain—multiple sclerosis	0.00104	0.00729	CbGeAlD
Paroxetine—SLC6A4—midbrain—multiple sclerosis	0.00104	0.00728	CbGeAlD
Paroxetine—SLC6A4—spinal cord—multiple sclerosis	0.00101	0.0071	CbGeAlD
Paroxetine—SLC6A2—medulla oblongata—multiple sclerosis	0.001	0.00701	CbGeAlD
Paroxetine—CHRM2—nervous system—multiple sclerosis	0.000934	0.00655	CbGeAlD
Paroxetine—SLC6A3—nervous system—multiple sclerosis	0.000932	0.00653	CbGeAlD
Paroxetine—CHRM2—central nervous system—multiple sclerosis	0.0009	0.00631	CbGeAlD
Paroxetine—SLC6A3—central nervous system—multiple sclerosis	0.000897	0.00629	CbGeAlD
Paroxetine—SLC6A3—cerebellum—multiple sclerosis	0.000877	0.00615	CbGeAlD
Paroxetine—HTR2A—brainstem—multiple sclerosis	0.000862	0.00604	CbGeAlD
Paroxetine—SLC6A4—nervous system—multiple sclerosis	0.000854	0.00598	CbGeAlD
Paroxetine—CHRM1—nervous system—multiple sclerosis	0.000851	0.00596	CbGeAlD
Paroxetine—HTR2A—retina—multiple sclerosis	0.000832	0.00583	CbGeAlD
Paroxetine—SLC6A4—central nervous system—multiple sclerosis	0.000822	0.00576	CbGeAlD
Paroxetine—CHRM1—central nervous system—multiple sclerosis	0.000819	0.00574	CbGeAlD
Paroxetine—CYP2D6—brainstem—multiple sclerosis	0.000786	0.00551	CbGeAlD
Paroxetine—CHRM3—nervous system—multiple sclerosis	0.000761	0.00533	CbGeAlD
Paroxetine—SLC6A2—nervous system—multiple sclerosis	0.000752	0.00527	CbGeAlD
Paroxetine—CHRM3—central nervous system—multiple sclerosis	0.000733	0.00514	CbGeAlD
Paroxetine—SLC6A2—central nervous system—multiple sclerosis	0.000724	0.00507	CbGeAlD
Paroxetine—CHRM2—brain—multiple sclerosis	0.000714	0.00501	CbGeAlD
Paroxetine—SLC6A3—brain—multiple sclerosis	0.000712	0.00499	CbGeAlD
Paroxetine—SLC6A4—brain—multiple sclerosis	0.000653	0.00457	CbGeAlD
Paroxetine—CHRM1—brain—multiple sclerosis	0.00065	0.00456	CbGeAlD
Paroxetine—HTR2A—medulla oblongata—multiple sclerosis	0.000601	0.00421	CbGeAlD
Paroxetine—CHRM3—brain—multiple sclerosis	0.000582	0.00408	CbGeAlD
Paroxetine—SLC6A2—brain—multiple sclerosis	0.000575	0.00403	CbGeAlD
Paroxetine—CYP2B6—nervous system—multiple sclerosis	0.000554	0.00388	CbGeAlD
Paroxetine—HTR2A—midbrain—multiple sclerosis	0.00055	0.00385	CbGeAlD
Paroxetine—ABCB1—retina—multiple sclerosis	0.000545	0.00382	CbGeAlD
Paroxetine—HTR2A—spinal cord—multiple sclerosis	0.000536	0.00376	CbGeAlD
Paroxetine—CYP2B6—central nervous system—multiple sclerosis	0.000533	0.00374	CbGeAlD
Paroxetine—CYP2C8—brain—multiple sclerosis	0.000472	0.00331	CbGeAlD
Paroxetine—HTR2A—nervous system—multiple sclerosis	0.000452	0.00317	CbGeAlD
Paroxetine—HTR2A—central nervous system—multiple sclerosis	0.000435	0.00305	CbGeAlD
Paroxetine—HTR2A—cerebellum—multiple sclerosis	0.000425	0.00298	CbGeAlD
Paroxetine—CYP2B6—brain—multiple sclerosis	0.000423	0.00297	CbGeAlD
Paroxetine—CYP2D6—nervous system—multiple sclerosis	0.000412	0.00288	CbGeAlD
Paroxetine—CYP2D6—central nervous system—multiple sclerosis	0.000396	0.00278	CbGeAlD
Paroxetine—ABCB1—medulla oblongata—multiple sclerosis	0.000394	0.00276	CbGeAlD
Paroxetine—CYP2D6—cerebellum—multiple sclerosis	0.000387	0.00271	CbGeAlD
Paroxetine—ABCB1—midbrain—multiple sclerosis	0.00036	0.00252	CbGeAlD
Paroxetine—ABCB1—spinal cord—multiple sclerosis	0.000351	0.00246	CbGeAlD
Paroxetine—HTR2A—brain—multiple sclerosis	0.000345	0.00242	CbGeAlD
Paroxetine—CYP2D6—brain—multiple sclerosis	0.000315	0.0022	CbGeAlD
Paroxetine—ABCB1—nervous system—multiple sclerosis	0.000296	0.00208	CbGeAlD
Paroxetine—ABCB1—central nervous system—multiple sclerosis	0.000285	0.002	CbGeAlD
Paroxetine—ABCB1—cerebellum—multiple sclerosis	0.000279	0.00195	CbGeAlD
Paroxetine—ABCB1—brain—multiple sclerosis	0.000226	0.00159	CbGeAlD
Paroxetine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000128	0.000333	CcSEcCtD
Paroxetine—Paraesthesia—Prednisolone—multiple sclerosis	0.000128	0.000333	CcSEcCtD
Paroxetine—Tachycardia—Triamcinolone—multiple sclerosis	0.000128	0.000333	CcSEcCtD
Paroxetine—Mental disorder—Prednisone—multiple sclerosis	0.000128	0.000332	CcSEcCtD
Paroxetine—Nausea—Azathioprine—multiple sclerosis	0.000128	0.000332	CcSEcCtD
Paroxetine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000128	0.000332	CcSEcCtD
Paroxetine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000127	0.00033	CcSEcCtD
Paroxetine—Erythema—Prednisone—multiple sclerosis	0.000127	0.00033	CcSEcCtD
Paroxetine—Malnutrition—Prednisone—multiple sclerosis	0.000127	0.00033	CcSEcCtD
Paroxetine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000127	0.000329	CcSEcCtD
Paroxetine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000127	0.000329	CcSEcCtD
Paroxetine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000126	0.000329	CcSEcCtD
Paroxetine—Convulsion—Betamethasone—multiple sclerosis	0.000126	0.000328	CcSEcCtD
Paroxetine—Convulsion—Dexamethasone—multiple sclerosis	0.000126	0.000328	CcSEcCtD
Paroxetine—Hypertension—Dexamethasone—multiple sclerosis	0.000126	0.000327	CcSEcCtD
Paroxetine—Hypertension—Betamethasone—multiple sclerosis	0.000126	0.000327	CcSEcCtD
Paroxetine—Asthenia—Mitoxantrone—multiple sclerosis	0.000125	0.000324	CcSEcCtD
Paroxetine—Myalgia—Betamethasone—multiple sclerosis	0.000124	0.000323	CcSEcCtD
Paroxetine—Myalgia—Dexamethasone—multiple sclerosis	0.000124	0.000323	CcSEcCtD
Paroxetine—Anxiety—Betamethasone—multiple sclerosis	0.000124	0.000321	CcSEcCtD
Paroxetine—Anxiety—Dexamethasone—multiple sclerosis	0.000124	0.000321	CcSEcCtD
Paroxetine—Discomfort—Dexamethasone—multiple sclerosis	0.000123	0.000319	CcSEcCtD
Paroxetine—Discomfort—Betamethasone—multiple sclerosis	0.000123	0.000319	CcSEcCtD
Paroxetine—Haemoglobin—Methotrexate—multiple sclerosis	0.000123	0.000318	CcSEcCtD
Paroxetine—Hypotension—Methylprednisolone—multiple sclerosis	0.000122	0.000318	CcSEcCtD
Paroxetine—Pain—Prednisolone—multiple sclerosis	0.000122	0.000317	CcSEcCtD
Paroxetine—Hepatitis—Methotrexate—multiple sclerosis	0.000122	0.000317	CcSEcCtD
Paroxetine—Haemorrhage—Methotrexate—multiple sclerosis	0.000122	0.000317	CcSEcCtD
Paroxetine—Pharyngitis—Methotrexate—multiple sclerosis	0.000121	0.000314	CcSEcCtD
Paroxetine—Vision blurred—Prednisone—multiple sclerosis	0.00012	0.000311	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000119	0.000311	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000119	0.00031	CcSEcCtD
Paroxetine—Oedema—Dexamethasone—multiple sclerosis	0.000119	0.000309	CcSEcCtD
Paroxetine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000119	0.000309	CcSEcCtD
Paroxetine—Oedema—Betamethasone—multiple sclerosis	0.000119	0.000309	CcSEcCtD
Paroxetine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000119	0.000309	CcSEcCtD
Paroxetine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000119	0.000309	CcSEcCtD
Paroxetine—Insomnia—Triamcinolone—multiple sclerosis	0.000119	0.000308	CcSEcCtD
Paroxetine—Insomnia—Methylprednisolone—multiple sclerosis	0.000118	0.000308	CcSEcCtD
Paroxetine—Infection—Betamethasone—multiple sclerosis	0.000118	0.000307	CcSEcCtD
Paroxetine—Infection—Dexamethasone—multiple sclerosis	0.000118	0.000307	CcSEcCtD
Paroxetine—Ill-defined disorder—Prednisone—multiple sclerosis	0.000118	0.000306	CcSEcCtD
Paroxetine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000118	0.000306	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000118	0.000305	CcSEcCtD
Paroxetine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000117	0.000305	CcSEcCtD
Paroxetine—Visual impairment—Methotrexate—multiple sclerosis	0.000117	0.000305	CcSEcCtD
Paroxetine—Anaemia—Prednisone—multiple sclerosis	0.000117	0.000305	CcSEcCtD
Paroxetine—Shock—Dexamethasone—multiple sclerosis	0.000117	0.000304	CcSEcCtD
Paroxetine—Shock—Betamethasone—multiple sclerosis	0.000117	0.000304	CcSEcCtD
Paroxetine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000117	0.000304	CcSEcCtD
Paroxetine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000117	0.000303	CcSEcCtD
Paroxetine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000117	0.000303	CcSEcCtD
Paroxetine—Agitation—Prednisone—multiple sclerosis	0.000117	0.000303	CcSEcCtD
Paroxetine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000117	0.000303	CcSEcCtD
Paroxetine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000117	0.000303	CcSEcCtD
Paroxetine—Tachycardia—Dexamethasone—multiple sclerosis	0.000116	0.000302	CcSEcCtD
Paroxetine—Tachycardia—Betamethasone—multiple sclerosis	0.000116	0.000302	CcSEcCtD
Paroxetine—Angioedema—Prednisone—multiple sclerosis	0.000116	0.000302	CcSEcCtD
Paroxetine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000115	0.0003	CcSEcCtD
Paroxetine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000115	0.0003	CcSEcCtD
Paroxetine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000115	0.000299	CcSEcCtD
Paroxetine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000115	0.000299	CcSEcCtD
Paroxetine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000115	0.000299	CcSEcCtD
Paroxetine—Malaise—Prednisone—multiple sclerosis	0.000114	0.000298	CcSEcCtD
Paroxetine—Vertigo—Prednisone—multiple sclerosis	0.000114	0.000296	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—multiple sclerosis	0.000114	0.000296	CcSEcCtD
Paroxetine—Syncope—Prednisone—multiple sclerosis	0.000114	0.000296	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—multiple sclerosis	0.000114	0.000295	CcSEcCtD
Paroxetine—Urticaria—Prednisolone—multiple sclerosis	0.000113	0.000294	CcSEcCtD
Paroxetine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000113	0.000294	CcSEcCtD
Paroxetine—Fatigue—Triamcinolone—multiple sclerosis	0.000113	0.000294	CcSEcCtD
Paroxetine—Fatigue—Methylprednisolone—multiple sclerosis	0.000113	0.000293	CcSEcCtD
Paroxetine—Pain—Triamcinolone—multiple sclerosis	0.000112	0.000291	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisone—multiple sclerosis	0.000112	0.00029	CcSEcCtD
Paroxetine—Hypotension—Dexamethasone—multiple sclerosis	0.000111	0.000289	CcSEcCtD
Paroxetine—Hypotension—Betamethasone—multiple sclerosis	0.000111	0.000289	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—multiple sclerosis	0.000111	0.000287	CcSEcCtD
Paroxetine—Vomiting—Mitoxantrone—multiple sclerosis	0.000111	0.000287	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—multiple sclerosis	0.00011	0.000286	CcSEcCtD
Paroxetine—Convulsion—Prednisone—multiple sclerosis	0.00011	0.000286	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00011	0.000286	CcSEcCtD
Paroxetine—Hypertension—Prednisone—multiple sclerosis	0.00011	0.000285	CcSEcCtD
Paroxetine—Rash—Mitoxantrone—multiple sclerosis	0.00011	0.000285	CcSEcCtD
Paroxetine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000109	0.000285	CcSEcCtD
Paroxetine—Chills—Methotrexate—multiple sclerosis	0.000109	0.000284	CcSEcCtD
Paroxetine—Headache—Mitoxantrone—multiple sclerosis	0.000109	0.000283	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000108	0.000282	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000108	0.000282	CcSEcCtD
Paroxetine—Myalgia—Prednisone—multiple sclerosis	0.000108	0.000281	CcSEcCtD
Paroxetine—Arthralgia—Prednisone—multiple sclerosis	0.000108	0.000281	CcSEcCtD
Paroxetine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000108	0.000281	CcSEcCtD
Paroxetine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000108	0.00028	CcSEcCtD
Paroxetine—Anxiety—Prednisone—multiple sclerosis	0.000108	0.00028	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—multiple sclerosis	0.000108	0.00028	CcSEcCtD
Paroxetine—Insomnia—Dexamethasone—multiple sclerosis	0.000108	0.00028	CcSEcCtD
Paroxetine—Insomnia—Betamethasone—multiple sclerosis	0.000108	0.00028	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000107	0.000279	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000107	0.000278	CcSEcCtD
Paroxetine—Paraesthesia—Betamethasone—multiple sclerosis	0.000107	0.000278	CcSEcCtD
Paroxetine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000107	0.000278	CcSEcCtD
Paroxetine—Discomfort—Prednisone—multiple sclerosis	0.000107	0.000278	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—multiple sclerosis	0.000107	0.000278	CcSEcCtD
Paroxetine—Erythema—Methotrexate—multiple sclerosis	0.000106	0.000276	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—multiple sclerosis	0.000106	0.000276	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000105	0.000273	CcSEcCtD
Paroxetine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000105	0.000272	CcSEcCtD
Paroxetine—Dyspepsia—Betamethasone—multiple sclerosis	0.000105	0.000272	CcSEcCtD
Paroxetine—Urticaria—Triamcinolone—multiple sclerosis	0.000104	0.000271	CcSEcCtD
Paroxetine—Urticaria—Methylprednisolone—multiple sclerosis	0.000104	0.00027	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—multiple sclerosis	0.000104	0.00027	CcSEcCtD
Paroxetine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000104	0.000269	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000104	0.000269	CcSEcCtD
Paroxetine—Oedema—Prednisone—multiple sclerosis	0.000104	0.000269	CcSEcCtD
Paroxetine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000103	0.000269	CcSEcCtD
Paroxetine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000103	0.000269	CcSEcCtD
Paroxetine—Decreased appetite—Betamethasone—multiple sclerosis	0.000103	0.000269	CcSEcCtD
Paroxetine—Nausea—Mitoxantrone—multiple sclerosis	0.000103	0.000268	CcSEcCtD
Paroxetine—Infection—Prednisone—multiple sclerosis	0.000103	0.000268	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000103	0.000267	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000103	0.000267	CcSEcCtD
Paroxetine—Back pain—Methotrexate—multiple sclerosis	0.000103	0.000267	CcSEcCtD
Paroxetine—Fatigue—Dexamethasone—multiple sclerosis	0.000103	0.000267	CcSEcCtD
Paroxetine—Fatigue—Betamethasone—multiple sclerosis	0.000103	0.000267	CcSEcCtD
Paroxetine—Shock—Prednisone—multiple sclerosis	0.000102	0.000265	CcSEcCtD
Paroxetine—Pain—Dexamethasone—multiple sclerosis	0.000102	0.000264	CcSEcCtD
Paroxetine—Pain—Betamethasone—multiple sclerosis	0.000102	0.000264	CcSEcCtD
Paroxetine—Nervous system disorder—Prednisone—multiple sclerosis	0.000102	0.000264	CcSEcCtD
Paroxetine—Tachycardia—Prednisone—multiple sclerosis	0.000101	0.000263	CcSEcCtD
Paroxetine—Skin disorder—Prednisone—multiple sclerosis	0.000101	0.000262	CcSEcCtD
Paroxetine—Hyperhidrosis—Prednisone—multiple sclerosis	0.0001	0.00026	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—multiple sclerosis	0.0001	0.00026	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—multiple sclerosis	9.85e-05	0.000256	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—multiple sclerosis	9.81e-05	0.000255	CcSEcCtD
Paroxetine—Feeling abnormal—Dexamethasone—multiple sclerosis	9.81e-05	0.000255	CcSEcCtD
Paroxetine—Feeling abnormal—Betamethasone—multiple sclerosis	9.81e-05	0.000255	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	9.73e-05	0.000253	CcSEcCtD
Paroxetine—Gastrointestinal pain—Betamethasone—multiple sclerosis	9.73e-05	0.000253	CcSEcCtD
Paroxetine—Hypersensitivity—Triamcinolone—multiple sclerosis	9.66e-05	0.000251	CcSEcCtD
Paroxetine—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.64e-05	0.000251	CcSEcCtD
Paroxetine—Malaise—Methotrexate—multiple sclerosis	9.57e-05	0.000249	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—multiple sclerosis	9.53e-05	0.000248	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—multiple sclerosis	9.5e-05	0.000247	CcSEcCtD
Paroxetine—Urticaria—Dexamethasone—multiple sclerosis	9.45e-05	0.000246	CcSEcCtD
Paroxetine—Urticaria—Betamethasone—multiple sclerosis	9.45e-05	0.000246	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	9.44e-05	0.000245	CcSEcCtD
Paroxetine—Dizziness—Prednisolone—multiple sclerosis	9.43e-05	0.000245	CcSEcCtD
Paroxetine—Asthenia—Triamcinolone—multiple sclerosis	9.41e-05	0.000245	CcSEcCtD
Paroxetine—Body temperature increased—Dexamethasone—multiple sclerosis	9.41e-05	0.000244	CcSEcCtD
Paroxetine—Abdominal pain—Betamethasone—multiple sclerosis	9.41e-05	0.000244	CcSEcCtD
Paroxetine—Abdominal pain—Dexamethasone—multiple sclerosis	9.41e-05	0.000244	CcSEcCtD
Paroxetine—Body temperature increased—Betamethasone—multiple sclerosis	9.41e-05	0.000244	CcSEcCtD
Paroxetine—Asthenia—Methylprednisolone—multiple sclerosis	9.39e-05	0.000244	CcSEcCtD
Paroxetine—Insomnia—Prednisone—multiple sclerosis	9.37e-05	0.000244	CcSEcCtD
Paroxetine—Paraesthesia—Prednisone—multiple sclerosis	9.3e-05	0.000242	CcSEcCtD
Paroxetine—Pruritus—Triamcinolone—multiple sclerosis	9.28e-05	0.000241	CcSEcCtD
Paroxetine—Cough—Methotrexate—multiple sclerosis	9.26e-05	0.000241	CcSEcCtD
Paroxetine—Pruritus—Methylprednisolone—multiple sclerosis	9.26e-05	0.000241	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—multiple sclerosis	9.19e-05	0.000239	CcSEcCtD
Paroxetine—Dyspepsia—Prednisone—multiple sclerosis	9.12e-05	0.000237	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—multiple sclerosis	9.03e-05	0.000235	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—multiple sclerosis	9.03e-05	0.000235	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—multiple sclerosis	9.03e-05	0.000235	CcSEcCtD
Paroxetine—Decreased appetite—Prednisone—multiple sclerosis	9.01e-05	0.000234	CcSEcCtD
Paroxetine—Rash—Prednisolone—multiple sclerosis	8.99e-05	0.000234	CcSEcCtD
Paroxetine—Dermatitis—Prednisolone—multiple sclerosis	8.98e-05	0.000233	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	8.97e-05	0.000233	CcSEcCtD
Paroxetine—Diarrhoea—Methylprednisolone—multiple sclerosis	8.95e-05	0.000233	CcSEcCtD
Paroxetine—Fatigue—Prednisone—multiple sclerosis	8.93e-05	0.000232	CcSEcCtD
Paroxetine—Headache—Prednisolone—multiple sclerosis	8.93e-05	0.000232	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—multiple sclerosis	8.93e-05	0.000232	CcSEcCtD
Paroxetine—Constipation—Prednisone—multiple sclerosis	8.86e-05	0.00023	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—multiple sclerosis	8.73e-05	0.000227	CcSEcCtD
Paroxetine—Dizziness—Triamcinolone—multiple sclerosis	8.67e-05	0.000225	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—multiple sclerosis	8.66e-05	0.000225	CcSEcCtD
Paroxetine—Dizziness—Methylprednisolone—multiple sclerosis	8.65e-05	0.000225	CcSEcCtD
Paroxetine—Infection—Methotrexate—multiple sclerosis	8.6e-05	0.000224	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisone—multiple sclerosis	8.54e-05	0.000222	CcSEcCtD
Paroxetine—Asthenia—Betamethasone—multiple sclerosis	8.54e-05	0.000222	CcSEcCtD
Paroxetine—Asthenia—Dexamethasone—multiple sclerosis	8.54e-05	0.000222	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—multiple sclerosis	8.49e-05	0.000221	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—multiple sclerosis	8.48e-05	0.00022	CcSEcCtD
Paroxetine—Gastrointestinal pain—Prednisone—multiple sclerosis	8.47e-05	0.00022	CcSEcCtD
Paroxetine—Nausea—Prednisolone—multiple sclerosis	8.47e-05	0.00022	CcSEcCtD
Paroxetine—Pruritus—Betamethasone—multiple sclerosis	8.42e-05	0.000219	CcSEcCtD
Paroxetine—Pruritus—Dexamethasone—multiple sclerosis	8.42e-05	0.000219	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—multiple sclerosis	8.41e-05	0.000219	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—multiple sclerosis	8.37e-05	0.000218	CcSEcCtD
Paroxetine—Vomiting—Triamcinolone—multiple sclerosis	8.34e-05	0.000217	CcSEcCtD
Paroxetine—Vomiting—Methylprednisolone—multiple sclerosis	8.32e-05	0.000216	CcSEcCtD
Paroxetine—Rash—Triamcinolone—multiple sclerosis	8.27e-05	0.000215	CcSEcCtD
Paroxetine—Dermatitis—Triamcinolone—multiple sclerosis	8.26e-05	0.000215	CcSEcCtD
Paroxetine—Rash—Methylprednisolone—multiple sclerosis	8.25e-05	0.000214	CcSEcCtD
Paroxetine—Dermatitis—Methylprednisolone—multiple sclerosis	8.24e-05	0.000214	CcSEcCtD
Paroxetine—Urticaria—Prednisone—multiple sclerosis	8.23e-05	0.000214	CcSEcCtD
Paroxetine—Headache—Triamcinolone—multiple sclerosis	8.22e-05	0.000214	CcSEcCtD
Paroxetine—Headache—Methylprednisolone—multiple sclerosis	8.2e-05	0.000213	CcSEcCtD
Paroxetine—Abdominal pain—Prednisone—multiple sclerosis	8.19e-05	0.000213	CcSEcCtD
Paroxetine—Body temperature increased—Prednisone—multiple sclerosis	8.19e-05	0.000213	CcSEcCtD
Paroxetine—Diarrhoea—Dexamethasone—multiple sclerosis	8.14e-05	0.000212	CcSEcCtD
Paroxetine—Diarrhoea—Betamethasone—multiple sclerosis	8.14e-05	0.000212	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—multiple sclerosis	8.09e-05	0.00021	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	7.89e-05	0.000205	CcSEcCtD
Paroxetine—Dizziness—Betamethasone—multiple sclerosis	7.87e-05	0.000205	CcSEcCtD
Paroxetine—Dizziness—Dexamethasone—multiple sclerosis	7.87e-05	0.000205	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—multiple sclerosis	7.83e-05	0.000204	CcSEcCtD
Paroxetine—Nausea—Triamcinolone—multiple sclerosis	7.79e-05	0.000202	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—multiple sclerosis	7.78e-05	0.000202	CcSEcCtD
Paroxetine—Nausea—Methylprednisolone—multiple sclerosis	7.77e-05	0.000202	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—multiple sclerosis	7.72e-05	0.000201	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—multiple sclerosis	7.7e-05	0.0002	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisone—multiple sclerosis	7.63e-05	0.000198	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—multiple sclerosis	7.62e-05	0.000198	CcSEcCtD
Paroxetine—Vomiting—Betamethasone—multiple sclerosis	7.57e-05	0.000197	CcSEcCtD
Paroxetine—Vomiting—Dexamethasone—multiple sclerosis	7.57e-05	0.000197	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—multiple sclerosis	7.53e-05	0.000196	CcSEcCtD
Paroxetine—Rash—Betamethasone—multiple sclerosis	7.5e-05	0.000195	CcSEcCtD
Paroxetine—Rash—Dexamethasone—multiple sclerosis	7.5e-05	0.000195	CcSEcCtD
Paroxetine—Dermatitis—Dexamethasone—multiple sclerosis	7.5e-05	0.000195	CcSEcCtD
Paroxetine—Dermatitis—Betamethasone—multiple sclerosis	7.5e-05	0.000195	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.48e-05	0.000194	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—multiple sclerosis	7.47e-05	0.000194	CcSEcCtD
Paroxetine—Headache—Betamethasone—multiple sclerosis	7.45e-05	0.000194	CcSEcCtD
Paroxetine—Headache—Dexamethasone—multiple sclerosis	7.45e-05	0.000194	CcSEcCtD
Paroxetine—Asthenia—Prednisone—multiple sclerosis	7.43e-05	0.000193	CcSEcCtD
Paroxetine—Pain—Methotrexate—multiple sclerosis	7.41e-05	0.000192	CcSEcCtD
Paroxetine—Pruritus—Prednisone—multiple sclerosis	7.33e-05	0.000191	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—multiple sclerosis	7.14e-05	0.000185	CcSEcCtD
Paroxetine—Diarrhoea—Prednisone—multiple sclerosis	7.09e-05	0.000184	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.08e-05	0.000184	CcSEcCtD
Paroxetine—Nausea—Betamethasone—multiple sclerosis	7.07e-05	0.000184	CcSEcCtD
Paroxetine—Nausea—Dexamethasone—multiple sclerosis	7.07e-05	0.000184	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—multiple sclerosis	6.88e-05	0.000179	CcSEcCtD
Paroxetine—Dizziness—Prednisone—multiple sclerosis	6.85e-05	0.000178	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—multiple sclerosis	6.85e-05	0.000178	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—multiple sclerosis	6.85e-05	0.000178	CcSEcCtD
Paroxetine—Vomiting—Prednisone—multiple sclerosis	6.59e-05	0.000171	CcSEcCtD
Paroxetine—Rash—Prednisone—multiple sclerosis	6.53e-05	0.00017	CcSEcCtD
Paroxetine—Dermatitis—Prednisone—multiple sclerosis	6.53e-05	0.00017	CcSEcCtD
Paroxetine—Headache—Prednisone—multiple sclerosis	6.49e-05	0.000169	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—multiple sclerosis	6.38e-05	0.000166	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—multiple sclerosis	6.21e-05	0.000161	CcSEcCtD
Paroxetine—Nausea—Prednisone—multiple sclerosis	6.16e-05	0.00016	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—multiple sclerosis	6.13e-05	0.000159	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—multiple sclerosis	5.93e-05	0.000154	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—multiple sclerosis	5.73e-05	0.000149	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—multiple sclerosis	5.51e-05	0.000143	CcSEcCtD
Paroxetine—Rash—Methotrexate—multiple sclerosis	5.46e-05	0.000142	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—multiple sclerosis	5.46e-05	0.000142	CcSEcCtD
Paroxetine—Headache—Methotrexate—multiple sclerosis	5.43e-05	0.000141	CcSEcCtD
Paroxetine—Nausea—Methotrexate—multiple sclerosis	5.14e-05	0.000134	CcSEcCtD
Paroxetine—ABCB1—Metabolism—RRM1—multiple sclerosis	2.79e-05	0.000203	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	2.79e-05	0.000203	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	2.78e-05	0.000202	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—POMC—multiple sclerosis	2.75e-05	0.0002	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCL2—multiple sclerosis	2.69e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL10—multiple sclerosis	2.68e-05	0.000195	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	2.65e-05	0.000193	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—POMC—multiple sclerosis	2.64e-05	0.000192	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL5—multiple sclerosis	2.64e-05	0.000192	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.63e-05	0.000192	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	2.63e-05	0.000191	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL5—multiple sclerosis	2.63e-05	0.000191	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL2—multiple sclerosis	2.62e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CCR5—multiple sclerosis	2.61e-05	0.00019	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.61e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CCR5—multiple sclerosis	2.61e-05	0.00019	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—multiple sclerosis	2.6e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL5—multiple sclerosis	2.6e-05	0.000189	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	2.59e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CCR5—multiple sclerosis	2.58e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CCL2—multiple sclerosis	2.58e-05	0.000188	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.58e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	2.58e-05	0.000187	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.57e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL10—multiple sclerosis	2.57e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2RA—multiple sclerosis	2.57e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2RA—multiple sclerosis	2.54e-05	0.000185	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—BCHE—multiple sclerosis	2.53e-05	0.000184	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.52e-05	0.000183	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.49e-05	0.000181	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—multiple sclerosis	2.48e-05	0.00018	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—TYK2—multiple sclerosis	2.44e-05	0.000178	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	2.42e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL3—multiple sclerosis	2.41e-05	0.000175	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.4e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL3—multiple sclerosis	2.4e-05	0.000175	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	2.39e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL3—multiple sclerosis	2.38e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCR5—multiple sclerosis	2.37e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCR5—multiple sclerosis	2.37e-05	0.000172	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	2.35e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CD86—multiple sclerosis	2.35e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCR5—multiple sclerosis	2.34e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—TYK2—multiple sclerosis	2.34e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2RA—multiple sclerosis	2.34e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2RA—multiple sclerosis	2.33e-05	0.00017	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	2.33e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTGER4—multiple sclerosis	2.32e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2RA—multiple sclerosis	2.31e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTGER4—multiple sclerosis	2.31e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL5—multiple sclerosis	2.31e-05	0.000168	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PGR—multiple sclerosis	2.29e-05	0.000167	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTGER4—multiple sclerosis	2.29e-05	0.000166	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PGR—multiple sclerosis	2.28e-05	0.000166	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PGR—multiple sclerosis	2.27e-05	0.000165	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PGR—multiple sclerosis	2.25e-05	0.000164	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	2.25e-05	0.000164	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CD86—multiple sclerosis	2.25e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—IL2—multiple sclerosis	2.24e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCR3—multiple sclerosis	2.24e-05	0.000163	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCR3—multiple sclerosis	2.23e-05	0.000162	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CD28—multiple sclerosis	2.23e-05	0.000162	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CD28—multiple sclerosis	2.22e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL5—multiple sclerosis	2.21e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CD28—multiple sclerosis	2.21e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCR3—multiple sclerosis	2.21e-05	0.000161	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—STAT3—multiple sclerosis	2.2e-05	0.00016	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	2.19e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CD28—multiple sclerosis	2.19e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR2—multiple sclerosis	2.18e-05	0.000158	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—BCHE—multiple sclerosis	2.18e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR2—multiple sclerosis	2.17e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR2—multiple sclerosis	2.15e-05	0.000156	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—IL2—multiple sclerosis	2.15e-05	0.000156	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SPP1—multiple sclerosis	2.14e-05	0.000156	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.14e-05	0.000156	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCR5—multiple sclerosis	2.08e-05	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	2.05e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2RA—multiple sclerosis	2.05e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SPP1—multiple sclerosis	2.05e-05	0.000149	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MYC—multiple sclerosis	2.05e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—POMC—multiple sclerosis	2.04e-05	0.000149	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—multiple sclerosis	2.04e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—POMC—multiple sclerosis	2.04e-05	0.000148	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL2—multiple sclerosis	2.03e-05	0.000148	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.02e-05	0.000147	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	2.02e-05	0.000147	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—POMC—multiple sclerosis	2.02e-05	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CNR1—multiple sclerosis	2.01e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CNR1—multiple sclerosis	2e-05	0.000146	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MAPK1—multiple sclerosis	2e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCR5—multiple sclerosis	1.99e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CNR1—multiple sclerosis	1.98e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2RA—multiple sclerosis	1.96e-05	0.000143	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.95e-05	0.000142	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL2—multiple sclerosis	1.95e-05	0.000142	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—APOE—multiple sclerosis	1.89e-05	0.000138	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	1.87e-05	0.000136	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—POMC—multiple sclerosis	1.86e-05	0.000135	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—POMC—multiple sclerosis	1.85e-05	0.000135	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.84e-05	0.000134	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—POMC—multiple sclerosis	1.83e-05	0.000133	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	1.83e-05	0.000133	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	1.82e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL2—multiple sclerosis	1.82e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—multiple sclerosis	1.81e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL2—multiple sclerosis	1.81e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL10—multiple sclerosis	1.81e-05	0.000132	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL10—multiple sclerosis	1.8e-05	0.000131	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL2—multiple sclerosis	1.79e-05	0.00013	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL10—multiple sclerosis	1.79e-05	0.00013	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.74e-05	0.000127	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CD80—multiple sclerosis	1.71e-05	0.000124	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	1.66e-05	0.000121	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TYK2—multiple sclerosis	1.65e-05	0.00012	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TYK2—multiple sclerosis	1.64e-05	0.00012	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CD80—multiple sclerosis	1.64e-05	0.000119	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TYK2—multiple sclerosis	1.63e-05	0.000118	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—multiple sclerosis	1.63e-05	0.000118	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.61e-05	0.000117	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—BCHE—multiple sclerosis	1.6e-05	0.000117	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL2—multiple sclerosis	1.59e-05	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.59e-05	0.000116	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.59e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CD86—multiple sclerosis	1.58e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CD86—multiple sclerosis	1.58e-05	0.000115	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.57e-05	0.000114	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CD86—multiple sclerosis	1.56e-05	0.000114	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—multiple sclerosis	1.56e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL5—multiple sclerosis	1.56e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MAPK1—multiple sclerosis	1.56e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL5—multiple sclerosis	1.55e-05	0.000113	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—multiple sclerosis	1.54e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL5—multiple sclerosis	1.54e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL2—multiple sclerosis	1.52e-05	0.000111	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—multiple sclerosis	1.52e-05	0.000111	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.52e-05	0.000111	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.51e-05	0.00011	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2—multiple sclerosis	1.51e-05	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2—multiple sclerosis	1.51e-05	0.00011	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.5e-05	0.000109	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2—multiple sclerosis	1.49e-05	0.000109	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MAPK1—multiple sclerosis	1.49e-05	0.000108	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.45e-05	0.000105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TYK2—multiple sclerosis	1.44e-05	0.000105	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPP1—multiple sclerosis	1.44e-05	0.000105	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPP1—multiple sclerosis	1.44e-05	0.000105	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPP1—multiple sclerosis	1.42e-05	0.000104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.41e-05	0.000103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR5—multiple sclerosis	1.4e-05	0.000102	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR5—multiple sclerosis	1.4e-05	0.000102	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.39e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR5—multiple sclerosis	1.38e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TYK2—multiple sclerosis	1.38e-05	0.000101	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2RA—multiple sclerosis	1.38e-05	0.000101	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.38e-05	0.0001	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2RA—multiple sclerosis	1.38e-05	0.0001	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2—multiple sclerosis	1.37e-05	9.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2—multiple sclerosis	1.37e-05	9.95e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2RA—multiple sclerosis	1.36e-05	9.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2—multiple sclerosis	1.35e-05	9.85e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—multiple sclerosis	1.31e-05	9.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—multiple sclerosis	1.31e-05	9.51e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.28e-05	9.33e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—multiple sclerosis	1.28e-05	9.28e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—multiple sclerosis	1.27e-05	9.26e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—multiple sclerosis	1.26e-05	9.17e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—multiple sclerosis	1.2e-05	8.75e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—multiple sclerosis	1.2e-05	8.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—multiple sclerosis	1.19e-05	8.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.16e-05	8.44e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CD80—multiple sclerosis	1.15e-05	8.39e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—multiple sclerosis	1.15e-05	8.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CD80—multiple sclerosis	1.15e-05	8.37e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—multiple sclerosis	1.15e-05	8.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CD80—multiple sclerosis	1.14e-05	8.29e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—multiple sclerosis	1.14e-05	8.28e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—multiple sclerosis	1.12e-05	8.18e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—multiple sclerosis	1.11e-05	8.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—multiple sclerosis	1.1e-05	8.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—multiple sclerosis	1.1e-05	7.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—multiple sclerosis	1.09e-05	7.95e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—multiple sclerosis	1.09e-05	7.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—multiple sclerosis	1.08e-05	7.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	1.08e-05	7.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	1.07e-05	7.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	1.07e-05	7.78e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	1.06e-05	7.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.05e-05	7.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	1.05e-05	7.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	1.05e-05	7.61e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	1.04e-05	7.54e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—multiple sclerosis	1.02e-05	7.46e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—multiple sclerosis	1.01e-05	7.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	9.79e-06	7.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	9.74e-06	7.09e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	9.71e-06	7.06e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—multiple sclerosis	9.68e-06	7.05e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—multiple sclerosis	9.65e-06	7.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	9.61e-06	7e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—multiple sclerosis	9.52e-06	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—multiple sclerosis	9.4e-06	6.84e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—multiple sclerosis	9.37e-06	6.82e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK1—multiple sclerosis	9.19e-06	6.69e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—multiple sclerosis	9.09e-06	6.62e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—multiple sclerosis	9.02e-06	6.56e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—multiple sclerosis	9e-06	6.55e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—multiple sclerosis	8.98e-06	6.53e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK1—multiple sclerosis	8.8e-06	6.41e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—multiple sclerosis	8.68e-06	6.31e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—multiple sclerosis	8.29e-06	6.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—multiple sclerosis	8.15e-06	5.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	8.11e-06	5.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—multiple sclerosis	8.1e-06	5.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—multiple sclerosis	8.08e-06	5.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	8.06e-06	5.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	8.04e-06	5.85e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—multiple sclerosis	8e-06	5.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	7.96e-06	5.79e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—multiple sclerosis	7.81e-06	5.69e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—multiple sclerosis	7.74e-06	5.64e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	7.71e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	7.67e-06	5.58e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	7.64e-06	5.56e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	7.57e-06	5.51e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—multiple sclerosis	7.56e-06	5.5e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—multiple sclerosis	7.12e-06	5.18e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—multiple sclerosis	7.06e-06	5.14e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—multiple sclerosis	7.06e-06	5.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	6.86e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	6.82e-06	4.96e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	6.8e-06	4.95e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—multiple sclerosis	6.76e-06	4.92e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	6.73e-06	4.9e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—multiple sclerosis	6.37e-06	4.64e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	6.35e-06	4.62e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—multiple sclerosis	6.34e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	6.32e-06	4.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—multiple sclerosis	6.32e-06	4.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	6.3e-06	4.58e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—multiple sclerosis	6.25e-06	4.55e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	6.24e-06	4.54e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	6.23e-06	4.53e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	6.2e-06	4.51e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	6.18e-06	4.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	6.12e-06	4.45e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—multiple sclerosis	4.79e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—multiple sclerosis	4.76e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—multiple sclerosis	4.75e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—multiple sclerosis	4.7e-06	3.42e-05	CbGpPWpGaD
